Trisha Jean Grevengoed

Trisha Jean Grevengoed

Auto-generated profile, based on publicly available information

Trisha Jean Grevengoed

Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2014 in Annual Review of Nutrition
Verified
Journal Article
Closed access
TGTrisha J. Grevengoed
Trisha J. Grevengoed
EKEric L. Klett
Eric L. Klett
RCRosalind A. Coleman
Rosalind A. Coleman
Long-chain fatty acyl-coenzyme As (CoAs) are critical regulatory molecules and metabolic intermediates. The initial step in their synthesis is the activation of fatty acids by one of 13 long-chain acyl-CoA synthetase isoforms. These isoforms are regulated independently and have different tissue expression patterns and subcellular locations. Their acyl-CoA products regulate metabolic enzymes and signaling pathways, become oxidized to provide cellular energy, and are incorporated into acylated proteins and complex lipids such as triacylglycerol, phospholipids, and cholesterol esters. Their differing metabolic fates are determined by a network of proteins that channel the acyl-CoAs toward or away from specific metabolic pathways and serve as the basis for partitioning. This review evaluates the evidence for acyl-CoA partitioning by reviewing experimental data on proteins that are believed to contribute to acyl-CoA channeling, the metabolic consequences of loss of these proteins, and the potential role of maladaptive acyl-CoA partitioning in the pathogenesis of metabolic disease and carcinogenesis.

1 May 2017 in Cell Metabolism
Verified
Journal Article
Closed access
SSSusanna Søberg
Susanna Søberg
CSCamilla H. Sandholt
Camilla H. Sandholt
NJNaja Z. Jespersen
Naja Z. Jespersen
UTUlla Toft
Ulla Toft
AMAnja L. Madsen
Anja L. Madsen
NGNiels Grarup
Niels Grarup

1 July 2018 in Cell Metabolism
Verified
Journal Article
Open access
ESElahu G. Sustarsic
Elahu G. Sustarsic
TMTao Ma
Tao Ma
MLMatthew D. Lynes
Matthew D. Lynes
MLMichael Larsen
Michael Larsen
IKIuliia Karavaeva
Iuliia Karavaeva
ZGZachary Gerhart-Hines
Zachary Gerhart-Hines
Activation of energy expenditure in thermogenic fat is a promising strategy to improve metabolic health, yet the dynamic processes that evoke this response are poorly understood. Here we show that synthesis of the mitochondrial phospholipid cardiolipin is indispensable for stimulating and sustaining thermogenic fat function. Cardiolipin biosynthesis is robustly induced in brown and beige adipose upon cold exposure. Mimicking this response through overexpression of cardiolipin synthase (Crls1) enhances energy consumption in mouse and human adipocytes. Crls1 deficiency in thermogenic adipocytes diminishes inducible mitochondrial uncoupling and elicits a nuclear transcriptional response through endoplasmic reticulum stress-mediated retrograde communication. Cardiolipin depletion in brown and beige fat abolishes adipose thermogenesis and glucose uptake, which renders animals insulin resistant. We further identify a rare human CRLS1 variant associated with insulin resistance and show that adipose CRLS1 levels positively correlate with insulin sensitivity. Thus, adipose cardiolipin has a powerful impact on organismal energy homeostasis through thermogenic fat bioenergetics.

28 July 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
LLLei O. Li
Lei O. Li
TGTrisha J. Grevengoed
Trisha J. Grevengoed
DPDavid S. Paul
David S. Paul
OIOlga Ilkayeva
Olga Ilkayeva
TKTimothy R. Koves
Timothy R. Koves
RCRosalind A. Coleman
Rosalind A. Coleman
Impaired capacity of skeletal muscle to switch between the oxidation of fatty acid (FA) and glucose is linked to disordered metabolic homeostasis. To understand how muscle FA oxidation affects systemic glucose, we studied mice with a skeletal muscle-specific deficiency of long-chain acyl-CoA synthetase-1 (ACSL1). ACSL1 deficiency caused a 91% loss of ACSL specific activity and 60-85% decreases in muscle FA oxidation. Acsl1M-/- mice were more insulin-sensitive, and during an overnight fast, their respiratory exchange ratio was higher, indicating greater glucose use. During endurance exercise, Acsl1M-/- mice ran only 48% as far as controls. At the time that Acsl1M-/- mice were exhausted but control mice continued to run, liver and muscle glycogen and triacylglycerol stores were similar in both genotypes; however, Acsl1M-/- plasma glucose concentrations were ∼40 mg/dl, whereas control glucose levels were ∼90 mg/dl. Excess use of glucose and the likely use of amino acids for fuel within muscle depleted glucose reserves and diminished substrate availability for hepatic gluconeogenesis. Surprisingly, the content of muscle acyl-CoA at exhaustion was markedly elevated, indicating that acyl-CoAs synthesized by other ACSL isoforms were not available for β-oxidation. This compartmentalization of acyl-CoAs resulted in both an excessive glucose requirement and severely compromised systemic glucose homeostasis.

1 May 2018 in Molecular Metabolism
Verified
Journal Article
Open access
SSSusanna Søberg
Susanna Søberg
EAEmilie S. Andersen
Emilie S. Andersen
NDNiels B. Dalsgaard
Niels B. Dalsgaard
IJIda Jarlhelt
Ida Jarlhelt
NHNina L. Hansen
Nina L. Hansen
MGMatthew Gillum
Matthew Gillum
Excessive alcohol consumption is a leading cause of global morbidity and mortality. However, knowledge of the biological factors that influence ad libitum alcohol intake may be incomplete. Two large studies recently linked variants in the KLB locus with levels of alcohol intake in humans. KLB encodes β-klotho, co-receptor for the liver-derived hormone fibroblast growth factor 21 (FGF21). In mice, FGF21 reduces alcohol intake, and human Fgf21 variants are enriched among heavy drinkers. Thus, the liver may limit alcohol consumption by secreting FGF21. However, whether full-length, active plasma FGF21 (FGF21 (1-181)) levels in humans increase acutely or sub-chronically in response to alcohol ingestion is uncertain. We recruited 10 healthy, fasted male subjects to receive an oral water or alcohol bolus with concurrent blood sampling for FGF21 (1-181) measurement in plasma. In addition, we measured circulating FGF21 (1-181) levels, liver stiffness, triglyceride, and other metabolic parameters in three healthy Danish men before and after consuming an average of 22.6 beers/person/day (4.4 g/kg/day of ethanol) for three days during Oktoberfest 2017 in Munich, Germany. We further correlated fasting FGF21 (1-181) levels in 49 healthy, non-alcoholic subjects of mixed sex with self-reports of alcohol-related behaviors, emotional responses, and problems. Finally, we characterized the effect of recombinant human FGF21 injection on ad libitum alcohol intake in mice. We show that alcohol ingestion (25.3 g or ∼2.5 standard drinks) acutely increases plasma levels of FGF21 (1-181) 3.4-fold in fasting humans. We also find that binge drinking for three days at Oktoberfest is associated with a 2.1-fold increase in baseline FGF21 (1-181) levels, in contrast to minor deteriorations in metabolic and hepatic biomarkers. However, basal FGF21 (1-181) levels were not correlated with differences in alcohol-related behaviors, emotional responses, or problems in our non-alcoholic subjects. Finally, we show that once-daily injection of recombinant human FGF21 reduces ad libitum alcohol intake by 21% in mice. FGF21 (1-181) is markedly increased in circulation by both acute and sub-chronic alcohol intake in humans, and reduces alcohol intake in mice. These observations are consistent with a role for FGF21 as an endocrine inhibitor of alcohol appetite in humans.

18 November 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TGTrisha J. Grevengoed
Trisha J. Grevengoed
STSam Trammell
Sam Trammell
MMMichele K. McKinney
Michele K. McKinney
NPNatalia Petersen
Natalia Petersen
RCRebecca L. Cardone
Rebecca L. Cardone
MGMatthew Gillum
Matthew Gillum
Significance: Deletion of fatty acid amide hydrolase (FAAH) in mice results in the concomitant elevation of 2 major types of fatty acid amides, N -acylethanolamines (NAEs) and N -acyl taurines (NATs), as well as obesity, hyperphagia, and insulin resistance. However, the respective contribution of each class of fatty acid amide to these phenotypes is unresolved. Here we employ an engineered variant of FAAH to specifically elevate NATs in vivo and administer the predominant circulating human NAT species to mice, demonstrating that NATs improve insulin sensitivity and augment secretion of the antidiabetic hormone GLP-1. These findings expose a divergent role for FAAH substrates in the regulation of glucose homeostasis, informing future efforts to target fatty acid amide signaling to treat metabolic disease.